First-in-Human Gene Therapy Trial for Type 1 Diabetes to Begin This Year with KRIYA-839
核心洞察
The PROGRESS study will mark the first clinical trial of an adeno-associated virus gene therapy for type 1 diabetes (搜索), enrolling adults to receive a single intramuscular injection of KRIYA-839.
The therapy converts muscle cells into insulin-producing factories by delivering genes for glucokinase (搜索) and insulin, potentially eliminating or significantly reducing daily insulin injections.
Pre-clinical studies demonstrated efficacy and safety in normalizing blood glucose levels in mouse and dog models for up to four years without immune suppression.
The first-ever clinical trial of an adeno-associated virus (AAV) gene therapy for type 1 diabetes (搜索) will begin this year, marking a significant milestone in diabetes treatment research. The PROGRESS study will evaluate KRIYA-839, a one-time intramuscular injection designed to convert patients' muscle cells into sustained insulin-producing factories.
Revolutionary Approach to Insulin Production
KRIYA-839 works by delivering two genes—for glucokinase (搜索) (GCK) and insulin—directly into quadriceps muscle cells using a non-pathogenic AAV vector. According to Dr. Jeremy Pettus, an endocrinologist and associate Professor of Medicine at the University of California-San Diego (搜索), who presented the research at the 19th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD) 2026 in Barcelona, the therapy represents a paradigm shift in diabetes management.
"In the type 1 community, we're used to hearing this will happen in 10 to 15 years' time, and maybe will come one day. So it's very exciting to stand here and say that this is actually something that's in the works and happening now," Pettus said.
The treatment involves several intramuscular injections, likely in both legs, administered during a single 30-60 minute outpatient clinic visit. The genes remain in the nuclei of muscle cells without integrating with the host genome, producing genetic material for insulin production throughout the patient's life.
Glucose-Responsive Insulin System
The therapy's design incorporates a sophisticated glucose-sensing mechanism. The muscle cells secrete insulin, which activates glucose transporter type 4 (搜索) to bring glucose into cells. Simultaneously, glucokinase (搜索) activates at higher glucose levels to move glucose out of the bloodstream while remaining inactive when blood glucose levels are low.
"So it has a glucose sensing kind of quality to it," Pettus noted, describing how the system mimics natural pancreatic function.
Strong Pre-Clinical Foundation
Pre-clinical data demonstrated both efficacy and safety of the gene products in normalizing blood glucose levels in mouse and dog models of type 1 diabetes (搜索) without immune suppression for up to four years. The therapy does not modify a person's DNA but introduces genetic instructions directly into muscle cells, enabling controlled insulin production over an extended period.
Trial Design and Patient Population
The 52-week phase 1 dose escalation study will enroll adults with type 1 diabetes (搜索) who have A1c levels above 7% while using automated insulin delivery systems. This specific patient population was chosen for safety reasons, ensuring that insulin dosing can be precisely quantified and de-escalated as needed.
Researchers expect the full therapeutic effect to set in within two to three months, with the potential for lifelong benefit. Treatment administration requires only a short course of "immune modulation" around the response to the virus capsid to facilitate uptake of genetic material into cells.
Clinical Significance and Expert Perspectives
Dr. Partha Kar, NHS England (搜索)'s national speciality adviser for diabetes, described the approach as "really exciting," adding, "If it works, it could help a lot of people." He noted that even a partial outcome, reducing insulin needs by as much as 75 percent, would represent a meaningful shift for patients.
However, experts maintain measured expectations. Tadej Battelino, head of endocrinology at UCH-UMC Ljubljana (搜索) and ATTD meeting co-chair, expressed cautious optimism: "I tend to be cautious, so I really can't give promises. Does this have a potential? Very much so."
Battelino suggested that if the therapy could achieve more than 70% of "time in tight range" (70-140 mg/dL), possibly in combination with technology, it could represent a functional cure. "I'm not saying it's a cure, but a functional cure, for sure," he stated.
Advantages Over Current Treatments
Unlike current transplants of cadaver or stem-cell derived islets that require immune suppression and are limited to patients with severe hypoglycemia or recurrent diabetic ketoacidosis, KRIYA-839 therapy "could potentially be for the masses" with type 1 diabetes (搜索), according to Pettus.
The advantages of AAV gene therapy include durable clinical benefit, single administration, no need for chronic immunosuppression, and broad patient eligibility. Pettus emphasized that "this is a proven technology" and that manufacturing improvements now allow expansion from rare, monogenic diseases to more common conditions like diabetes.
Type 1 diabetes (搜索) is a chronic autoimmune condition affecting hundreds of thousands of patients, who must monitor blood sugar regularly and rely on daily insulin injections or insulin pumps to maintain glucose control. The potential for a single treatment to provide sustained insulin production represents a transformative approach to managing this lifelong condition.